Gemphire Therapeutics Inc. and Phaserx Inc. have become the latest brave entrants to the biopharma IPO queue, joining 17 other contenders filed and pending, in a public financing climate significantly cooler than in 2015. Gemphire, a cardiovascular-focused clinical company with a midstage dyslipidemia drug, is seeking a proposed $60 million, while Phaserx, a preclinical company working on treatments for inherited enzyme deficiencies, has proposed raising up to $25.3 million.